Post-Marketing Surveillance of Polatuzumab Vedotin: A Disproportionality Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Muscara, Claudia [1 ]
Allegra, Alessandro [2 ]
Tuccoli, Marco [3 ]
Flaccavento, Alessandra [4 ]
Cutroneo, Paola Maria [1 ]
机构：
[1] Univ Hosp Messina, Sicilian Reg Pharmacovigilance Ctr, Clin Pharmacol Unit, Messina, Italy
[2] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Hematol Unit, Messina, Italy
[3] Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Pisa, Italy
[4] Univ Pisa, Dept Clin & Expt Med Sect Pharmacol & Pharmacovig, Pisa, Italy
来源：
DRUG SAFETY | 2024年 / 47卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
210
引用
收藏
页码：1408 / 1408
页数：1
相关论文
共 50 条
  • [21] Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS)
    Stamoula, Eleni
    Stamatellos, Vasileios-Periklis
    Vavilis, Theofanis
    Dardalas, Ioannis
    Papazisis, Georgios
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 239 - 245
  • [22] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] Disproportionality analysis of adverse events associated with asfotase alfa: a post-marketing study using the FDA Adverse Event Reporting System
    Wang, Wen
    Wang, Zhe
    Chen, Qianxiu
    Sun, Haixia
    Fu, Zongchao
    Han, Jing
    Lv, Hao
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [24] Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
    Shu, Yamin
    Wang, Lei
    Ding, Yiling
    Zhang, Qilin
    DRUG SAFETY, 2023, 46 (09) : 881 - 895
  • [25] Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
    Yamin Shu
    Lei Wang
    Yiling Ding
    Qilin Zhang
    Drug Safety, 2023, 46 : 881 - 895
  • [26] Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
    Gastaldon, Chiara
    Raschi, Emanuel
    Kane, John M.
    Barbui, Corrado
    Schoretsanitis, Georgios
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 90 (01) : 41 - 48
  • [27] A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
    Liu, Dan
    Mao, Wei
    Hu, Bin
    Li, Xingxing
    Zhao, Quanfeng
    Zhang, Lin
    Hu, Jing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database
    Kumar, Nitin
    Kalaiselvan, Vivekanandan
    Arora, Mandeep Kumar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1685 - 1695
  • [29] Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
    Zhuang, Wei
    Xu, Jiabing
    Wu, Ye
    Yang, Jianhui
    Lin, Xiuxian
    Liao, Yufang
    Wan, Jun
    Weng, Lizhu
    Lin, Wanlong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (09) : 2830 - 2842
  • [30] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
12345